Soliris is an intravenous humanized monoclonal antibody for the treatment of acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis. Soliris was initially Food and Drug Administration (FDA) approved in 2007 for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis. The approval was expanded in 2011 to include treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy.

If you have a Hayes login, click here to view the full report on the Knowledge Center.